Navigation Links
3SBio Inc. Files for SFDA Approval of NuLeusin
Date:11/10/2008

SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval of NuLeusin for the treatment of late stage metastatic renal cell carcinoma. If approved, NuLeusin is expected to be the only treatment of this kind available in China.

NuLeusin, 3SBio's second-generation IL-2, is a genetically modified form of IL-2 possessing improved biochemical properties over naturally occurring IL-2. Clinical trials examined the safety and efficacy of two treatment cycles of subcutaneous injections of NuLeusin. During each six-week treatment cycle, patients were given daily doses of 7MIU/square meter in the induction phase and daily doses of 3.5MIU/square meter in the maintenance phase. The results showed an overall efficacy (Complete Response +Partial Response) of 12.73% and a disease control rate (Complete Response+ Partial Response+ Stable Disease) of 60%. Compared to Chiron's Proleukin, a treatment available in the United States, which is believed to be the only similar product on the market today, Nuleusin demonstrated similar levels of efficacy with a much lower dosage. More importantly, NuLeusin showed an improved safety and tolerability profile in patients who participated in the Phase III study.

"Today's submission comes only a little over one month following our submission for high dosage EPIAO and once again demonstrates our outstanding research and development capabilities and our strong ability to execute on our business plan," stated Dr. Jing Lou, Chief Executive Officer of 3SBio. "NuLeusin was developed to provide a new immunotherapy regimen for oncologists to treat patients with late stage metastatic renal cell carcinoma. Upon approval, we believe many patients who have exhausted their treatment options will benefit from this new alternative. In addition, Nuleusin is expected to further expand 3SBio's existing presence in the rapidly growing oncology market in China."

About the Phase III Study

The Phase III study was a multi-center, open label, single arm study carried out in nine first-tier hospitals in Beijing. The study enrolled 75 patients with post surgery renal cell carcinoma metastasis into two six-week treatment cycles, with a two-week break between each cycle. Patients were given subcutaneous injections of 3.5MIU/ square meter NuLeusin every twelve hours, twice a day, for five consecutive days in the first week of each treatment cycle during the induction phase. From the second week onward, during the maintenance phase, patients received daily subcutaneous injections of 3.5MIU/square meter NuLeusin for five consecutive days each week. The maximum number of treatment cycles patients could receive was three. The clinical endpoint was assessed using computerized tomography scan image of tumor response.

The results of Phase III study demonstrated NuLeusin to be an effective treatment for metastatic renal cell carcinoma with improved safety and tolerability, with an overall efficacy of 12.73% and a disease control rate of 60% (per protocol site). The possible causes for the difference in efficacy compared to Proleukin could be variations in patient race, injection dosage, and route of administration and treatment time. The most common adverse effect related to NuLeusin was low fever and injection site reactions.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at: http://www.3sbio.com.

Safe Harbor Statement

Statements in this release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; the completion of 3SBio's ongoing clinical trials as planned; receipt and timing of regulatory approvals for 3SBio's new products and uses; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio's financial results, please refer to the company's filings with the Securities and Exchange Commission at http://www.sec.gov . 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

For more information, please contact:

Investor Contact:

David Chen, COO

3SBio Inc.

Tel: +86-24-2581-1820

Investor Relations (US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Investor Relations (HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Media Contact:

Jason Marshall

Taylor Rafferty

Tel: +1-212-889-4350


'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
2. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
3. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
4. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
5. 3SBio Inc. Announces Results of Annual General Meeting
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. Announces Second Quarter 2008 Results
9. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
10. 3SBio Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
11. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing ... MPH, will present information about the company,s programs at the BIOCEO ... New York City . --> ... 5:30PM EST. Registered attendees can request a one on one meeting ... --> New York City . ...
(Date:2/6/2016)... Virginia (PRWEB) , ... February 06, 2016 , ... ... E-mail: amitchell(at)cee(dot)org , The Center for Excellence in Education Sponsors Teacher Training ... VA – February 4, 2016 – The Center for Excellence in Education (CEE) ...
(Date:2/5/2016)... drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ: ... Mr John O,Connor , and new Deputy Chairman, Mr ... Garner , has also been formally appointed to the Board ... Iain Ross , will resume his role on the Board ... has also been formally appointed to the Board as an ...
(Date:2/4/2016)... (PRWEB) , ... February 04, ... ... conference presented by Bloomsburg University’s Digital Forensics Club, takes place February 5-6 ... two-day event features 20+ speakers and activities such as workshops and competitions ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016 Technology Enhancements Accelerate Growth of ... of the digital and computed radiography markets in ... and Indonesia (TIM). It provides ... size, as well as regional market drivers and restraints. ... market penetration and market attractiveness, both for digital and ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/25/2016)... BLUE BELL, Pa. , Jan. 25, 2016   Unisys ... facial recognition system at John F. Kennedy (JFK) International Airport, ... and Border Protection (CBP) identify imposters attempting to enter ... or do not belong to them. pilot testing ... rolled out initially at three terminals at JFK during January 2016. ...
Breaking Biology News(10 mins):